DepoCyte
cytarabine
Table of contents
Overview
The marketing authorisation for DepoCyte has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
DepoCyte
|
| Agency product number |
EMEA/H/C/000317
|
| Active substance |
cytarabine
|
| International non-proprietary name (INN) or common name |
cytarabine
|
| Therapeutic area (MeSH) |
Meningeal Neoplasms
|
| Anatomical therapeutic chemical (ATC) code |
L01BC01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pacira Limited
|
| Revision |
15
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/07/2001
|
| Contact address |
3 Glory Park Avenue
Wooburn Green High Wycombe Buckinghamshire HP10 0DF United Kingdom |
Product information
26/06/2017 DepoCyte - EMEA/H/C/000317 - N/0059
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.